No headlines found.
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
Globe Newswire (Tue, 9-Dec 8:35 AM ET)
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
Inmed Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol INM.
As of February 3, 2026, INM stock price declined to $1.06 with 95,670 million shares trading.
INM has a beta of 3.30, meaning it tends to be more sensitive to market movements. INM has a correlation of 0.33 to the broad based SPY ETF.
INM has a market cap of $2.97 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INM traded as high as $46.60 and as low as $1.03.
INM has underperformed the market in the last year with a price return of -65.6% while the SPY ETF gained +15.8%. INM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.6% and -3.6%, respectively, while the SPY returned +1.4% and -0.3%, respectively.
INM support price is $1.04 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INM shares will trade within this expected range on the day.
